Our history

A century of leadership in allergy immunotherapy

The ALK-Abelló Group was established nearly 100 years ago with the mission of building a leadership position in the development, production and distribution of high-quality allergenic extracts

Explore ALK's rich history

  • June, 1923
    ALK's foundation
    Doctor Kaj Baagøe and pharmacist Poul Barfod produce Denmark’s first pharmaceutically manufactured allergen extract at Copenhagen University Hospital
  • June, 1949
    Dedicated facilities
    Production of allergy immunotherapy treatments and diagnostics is centered at an independent unit called Allergologisk Laboratorium København (Allergology Laboratory Copenhagen)
  • June, 1972
    A new industry standard
    ALK develops the technique to accurately identify the proteins that provoke allergies and a standardized process for manufacturing allergen extracts
  • June, 1978
    A world first
    The world’s first standardized allergy immunotherapy is launched by ALK
  • June, 1990
    Groundbreaking asthma research
    ALK collaborates on research that shows allergy immunotherapy decreases the risk of developing asthma in children with allergic rhinitis
  • July, 2006
    First SLIT-tablets
    The world’s first sublingual allergy immunotherapy tablet (SLIT-tablet) is approved in Europe.
  • July, 2009
    SLIT-tablet approved as a disease-modifying treatment
    ALK's SLIT-tablet the only one to be approved as a disease-modifying treatment for grass pollen allergy
  • July, 2016
    GAP-trial demonstrates reduced asthma symptoms
    Trial in children demonstrates that ALK's grass pollen SLIT-tablet reduces the risk in development of asthma symptoms and/or use of asthma medication in children with grass pollen allergic rhinitis
  • November, 2016
    US subsidiary established
    ALK-Abelló, Inc., the US subsidiary, was established in 1984 to introduce the high quality SQ product line to the US allergy market. SQ Cat Hair was the first product introduced. It was very well received by the allergy community and continues to be one of our most popular products.
ALK's foundation Doctor Kaj Baagøe and pharmacist Poul Barfod produce Denmark’s first pharmaceutically manufactured allergen extract at Copenhagen University Hospital
June, 1923
Dedicated facilities Production of allergy immunotherapy treatments and diagnostics is centered at an independent unit called Allergologisk Laboratorium København (Allergology Laboratory Copenhagen)
June, 1949
A new industry standard ALK develops the technique to accurately identify the proteins that provoke allergies and a standardized process for manufacturing allergen extracts
June, 1972
A world first The world’s first standardized allergy immunotherapy is launched by ALK
June, 1978
Groundbreaking asthma research ALK collaborates on research that shows allergy immunotherapy decreases the risk of developing asthma in children with allergic rhinitis
June, 1990
First SLIT-tablets The world’s first sublingual allergy immunotherapy tablet (SLIT-tablet) is approved in Europe.
July, 2006
SLIT-tablet approved as a disease-modifying treatment ALK's SLIT-tablet the only one to be approved as a disease-modifying treatment for grass pollen allergy
July, 2009
GAP-trial demonstrates reduced asthma symptoms Trial in children demonstrates that ALK's grass pollen SLIT-tablet reduces the risk in development of asthma symptoms and/or use of asthma medication in children with grass pollen allergic rhinitis
July, 2016
US subsidiary established ALK-Abelló, Inc., the US subsidiary, was established in 1984 to introduce the high quality SQ product line to the US allergy market. SQ Cat Hair was the first product introduced. It was very well received by the allergy community and continues to be one of our most popular products.
November, 2016
  • ALK's foundation
    June, 1923
    Doctor Kaj Baagøe and pharmacist Poul Barfod produce Denmark’s first pharmaceutically manufactured allergen extract at Copenhagen University Hospital
  • Dedicated facilities
    June, 1949
    Production of allergy immunotherapy treatments and diagnostics is centered at an independent unit called Allergologisk Laboratorium København (Allergology Laboratory Copenhagen)
  • A new industry standard
    June, 1972
    ALK develops the technique to accurately identify the proteins that provoke allergies and a standardized process for manufacturing allergen extracts
  • A world first
    June, 1978
    The world’s first standardized allergy immunotherapy is launched by ALK
  • Groundbreaking asthma research
    June, 1990
    ALK collaborates on research that shows allergy immunotherapy decreases the risk of developing asthma in children with allergic rhinitis
  • First SLIT-tablets
    July, 2006
    The world’s first sublingual allergy immunotherapy tablet (SLIT-tablet) is approved in Europe.
  • SLIT-tablet approved as a disease-modifying treatment
    July, 2009
    ALK's SLIT-tablet the only one to be approved as a disease-modifying treatment for grass pollen allergy
  • GAP-trial demonstrates reduced asthma symptoms
    July, 2016
    Trial in children demonstrates that ALK's grass pollen SLIT-tablet reduces the risk in development of asthma symptoms and/or use of asthma medication in children with grass pollen allergic rhinitis
  • US subsidiary established
    November, 2016
    ALK-Abelló, Inc., the US subsidiary, was established in 1984 to introduce the high quality SQ product line to the US allergy market. SQ Cat Hair was the first product introduced. It was very well received by the allergy community and continues to be one of our most popular products.
Last updated: 2016.12.01